Introduction 22
The prevalence of multidrug-resistant TB (MDRTB) is rising globally, posing a serious threat to 23 tuberculosis (TB) control. (25) MDRTB does not respond to treatment with first-line drugs, (3) 24 and its management using second-line drugs has not yet been properly organized by most control 25 programmes. (25) Although MDRTB is defined as resistance to at least isoniazid and rifampin 26 (RMP), the key determinant for treatment failure is RMP resistance. Detection of RMP resistance 27 has thus been proposed as a proxy for MDRTB diagnosis as well as for epidemiological 28 monitoring. (14, 20, 24) RMP drug susceptibility testing (DST) is generally considered as most 29 reliable, by conventional methods based on growth as well as by newer genetic techniques. (1, 8) approximately 50% resistance to all first-line TB drugs in various combinations. This pre-37 condition resulted in over-representation of rare profiles. The SRLs employed one of the four 38 recognized standard culture-based DST methods and the discordant results were not clearly 39 correlated with a particular method or systematic technical errors. DNA-sequencing of the PT 40 rounds' problem strains invariably showed some rpoB gene mutation. All the mutations 41 encountered had been described previously and were generally considered to confer RMP-42 resistance, though sometimes at a low level, (12) including those outside Cluster I of the core region, (15) Presence of a mutation described as conferring resistance to RMP thus took precedence over 63 treatment outcome, since it is known that patients may fail or relapse from treatment due to other 64 reasons than (RMP) drug resistance, while conversely a low proportion of tuberculosis patients 65 seem to cure spontaneously, independent of drug resistance. (3, 6) Table 1 
